Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Antimicrobial resistance is a growing threat, with treatment options urgently needed for patients at risk of MDR Gram-negative infections1,2cIAI pasient Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.2cIAI patient profile*

Identifying patients with cIAI at high-risk of MDR Gram-negative infections.

 Michael 75-year-old male

Patient history

  • Type II diabetes mellitus
  • Underwent segmental colon resection and primary anastomosis with peri-operative antibiotic therapy
  • Previous broad-spectrum
  • IV antibiotic use
  • Recent travel

Symptoms
Infection symptoms include:

  • Acute-onset abdominal pain that developed into diffuse pain
  • Fever
  • Loss of appetite
  • Nausea
Diagnosis
  • Admission to ICU
  • Complicated diverticulitis
  • Diarrhoea

Suspected pathogens

MDR Gram-negative pathogens, including K. pneumoniae, possibly 
carbapenem- and colistin-resistant
Michael75-year-old male

Patient History

  • Type II diabetes mellitus
  • Underwent segmental colon resection and primary anastomosis with peri-operative antibiotic therapy
  • Previous broad-spectrum
  • IV antibiotic use
  • Recent travel

Symptoms
Infection symptoms include:

  • Acute-onset abdominal pain that developed into diffuse pain
  • Fever
  • Loss of appetite
  • Nausea
Diagnosis
  • Admission to ICU
  • Complicated diverticulitis
  • Diarrhoea

Suspected pathogens

MDR Gram-negative pathogens, including K. pneumoniae, possibly 
carbapenem- and colistin-resistant
Patient risk factors for a MDR 
Gram-negative infection Why ZAVICEFTA is an appropriate choice for your cIAI patients ZAVICEFTA when combined with metronidazole: As effective as best available therapy with Gram-negative cIAI.12Explore moreInfectious Thinking

Listen to episode 4 of our ‘Infectious Thinking’ podcast on high-risk paediatric patients with cIAI.

LoadingcIAI

Learn more about our cIAI clinical trial efficacy.

LoadingPrescribing information

View ZAVICEFTA prescribing information.

Loading
Footnotes:*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA (ceftazidime–avibactam) could be considered.
†Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and does not inhibit many class D enzymes.8
§To be used in combination with metronidazole when anaerobic pathogens are known or suspected to
be contributing to the infectious process.8
To be used in combination with an antibacterial agent active against Gram-positive pathogens when
these are known or suspected to be contributing to the infectious process.8Abbreviations:COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacterales; cIAI, complicated intra-abdominal infection; ESBL, extended spectrum beta-lactamase; HAP, hospital-acquired pneumonia; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase; VAP, ventilator-associated pneumoniaReferences:Timsit J-F, et al. Intensive Care Med 2019; 45:573–91.Bonine NG, et al. Am J Med Sci 2019;357:102–10.Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65.Miller BM, et al. Am J Infect Control 2016;44:134–7.De Waele J, et al. Intensive Care Med 2018;44:189–96.Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23.Harris AD, et al. Emerg Infect Dis 2007;13:1144–9.ZAVICEFTA. Summary of Product Characteristics, 2022.Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.Zhanel GG, et al. Drugs 2013;73:159–77.Mazuski JE, et al. Surg Infect 2017;18:1–76.Mazuski JE, et al. Clin Infect Dis 2016;62 1380–9.Torres A, et al. Lancet Infect Dis 2018;18:285–95.Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.
Pasientprofiler
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei